Biodexa Pharmaceuticals annual gross margin
2015
2016
2017
2022
2023
Biodexa Pharmaceuticals Gross Margin Growth & History (BDRX)
Biodexa Pharmaceuticals's gross margin was −967.45% for fiscal 2023.
View full Biodexa Pharmaceuticals company overviewBiodexa Pharmaceuticals annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2023 | 2023-12-31 | −967.45% | −336.27 pp |
| 2022 | 2022-12-31 | −631.19% | — |
| 2017 | 2017-12-31 | 674.62% | +201.76 pp |
| 2016 | 2016-12-31 | 472.86% | +377.96 pp |
| 2015 | 2015-12-31 | 94.91% | — |
Biodexa Pharmaceuticals gross margin trends
Between the periods ended 2015-12-31 and 2023-12-31, Biodexa Pharmaceuticals's gross margin decreased from 94.91% to −967.45%, a change of −1062.36 percentage points.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biodexa Pharmaceuticals source filings ↗Community posts
Biodexa advances trial enrollment as research spending and cash use rise
Biodexa ($BDRX) reported that 92 of the planned 168 participants have entered its Serenta trial, while first-half research and development spending increased to £2.92 million from £1.67 million. Spending reflected the trial and manufacturin ...
